期刊文献+

白细胞介素18受体和CD30抗原在移植肾组织中的表达 被引量:1

Expression of interleukin 18 receptor and CD30 antigen in kidney transplant nephrectomy specimens
下载PDF
导出
摘要 目的:探讨白细胞介素18受体(IL18R)和CD30抗原在移植肾排异反应中的局部表达及其临床意义。方法:采用链霉亲合素过氧化物酶(SP)免疫组织化学法检测44例移植肾切除标本[其中超急性排异反应(HAR)8例,急性排异反应(AR)16例,慢性排异反应(CR)12例和非免疫因素导致肾功能损害8例]及6例正常肾组织中IL18R和CD30的表达。结果:IL18R表达主要发生在肾小管上皮细胞,胞质表达为主。正常对照组肾小管上皮细胞表达为+~++,肾小球系膜细胞无表达。HAR、AR肾小管及肾小球的表达明显增强。CR组IL18R表达减弱。正常对照组肾小球、肾小管上皮细胞均无CD30抗原表达。HAR肾小球系膜细胞CD30(+),其余各组肾小球系膜细胞均无CD30抗原表达。CD30阳性均表现为胞质表达。肾小管上皮细胞CD30抗原表达多见于HAR和AR。CR及其他组肾小管上皮细胞CD30抗原表达较少。结论:IL18R和CD30抗原可能参与HAR、AR过程。检测IL18R和CD30抗原可为评价移植肾病理改变和肾移植预后提供重要参考。 Objective:To investigate the effects of Interleukin-18 receptor (IL-18R) and CD30 antigen in renal transplant allograft rejection. Methods: Paraffin-embedded kidney transplant nephrectomy specimens from 44 patients of allografted kidney, including eight with hyperacute rejection(HAR), sixteen with acute rejection(AR), twelve with chronic rejection(CR) and eight with damaged renal function by other factors, were conducted to examine IL-18R and CD30 antigen expression by ultra-sensitive S-P immunohistochemical staining . Results: IL-18R and CD30 antigen positive expression were mainly observed at the renal tubular epithelia in AR and HAR. The degree of IL-18R,CD30 antigen positive expression was associated with the degree of pathological damage in HAR and AR, and was significantly higher than normal control,CR and damaged kidney by nonimmunologic causes. Conclusions:IL-18R and CD30 antigen might participate in HAR and AR. Detection of IL-18R and CD30 antigen expression might be an important parameter to evaluate the pathological changes and prognosis in the renal allograft transplantation.
出处 《临床泌尿外科杂志》 2006年第5期334-336,共3页 Journal of Clinical Urology
关键词 白细胞介素18受体 CD30抗原 肾移植 排异反应 免疫组化 Interleukin-18 receptor CD30 antigen Renal transplantation Rejection Immunohistochemical staining
  • 相关文献

参考文献5

  • 1Matsuno T, Sasaki H, Nakagawa K, et al. Fas antigen expression and apoptosis in kidney allografts [J].Transp Proc,1997,29: 177- 178.
  • 2Zhang Z X, Yang L, Young K J, et al. Identification of a previously unknown antigen-specific regulatory T cells and its mechanism of suppression[J]. Nat Med,2000,6:782-789.
  • 3Yamaguchi Y, Matsumura F, Liang J, et al. Reduced interleukin-12, interleukin-18, and interferon-gamma production with prolonged rat hepatic allograft survival after donor-specific blood transfusion[J]. Dig Dis Sci,2000,45(12): 2429-2435.
  • 4Amakawa R. Impaired negative selection of T cells in Hodgkin's disease antigen CD30-deficient mice [J].Cell, 1996,84:551 - 562.
  • 5Gerli R. CD30 + T cells in rheumatoid synovitis:mechanisms of recruitment and functional role [J]. J Immunol, 2000,164 :4399 - 4407.

同被引文献14

  • 1Okamura H,Tsutsi H,Komatsu T,et al.Cloning of a new cytokine that induces IFN-gamma production by T cells.Nature.1995;378(6552):88-91.
  • 2Roberti I,Reisman L.Serial evaluation of cell surface markers for immune activation after acute renal allograft rejection by urine flow cytometry——correlation with clinical outcome.Transplantation.2001;71(9):1317-1320.
  • 3Woodle ES,Cronin D,Newell KA,et al.Tacrolimus therapy for refractory acute renal allograft rejection:definition of the histologic response by protocol biopsies.Transplantation.1996;62(7):906-910.
  • 4Beckingham IJ,Nicholson ML,Bell PR.Analysis of factors associated with complications following renal transplant needle core biopsy.Br J Urol.1994;73(1):13-15.
  • 5Benfield MR,Herrin J,Feld L,et al.Safety of kidney biopsy in pediatric transplantation:a report of the Controlled Clinical Trials in Pediatric Transplantation Trial of Induction Therapy Study Group.Transplantation.1999;67(4):544-547.
  • 6Ishida H,Koyama I,Sawada T,et al.Clinical utility of monitoring sialyl Lewis(X) (CD15S) antigen on peripheral lymphocytes for the diagnosis and treatment of rejection after renal transplantation.Transplantation.2000;69(1):59-63.
  • 7García-Alonso AM,Minguela A,Muro M,et al.CD28 expression on peripheral blood T lymphocytes after orthotopic liver transplant:upregulation in acute rejection.Hum Immunol.1997;53(1):64-72.
  • 8Dinarello CA.Interleukin-18.Methods.1999;19(1):121-132.
  • 9Fujimori Y,Takatsuka H,Takemoto Y,et al.Elevated interleukin (IL)-18 levels during acute graft-versus-host disease after allogeneic bone marrow transplantation.Br J Haematol.2000;109(3):652-657.
  • 10Fujimori Y,Yoshimoto T,Matsui K,et al.Increased expression of interleukin-18 receptor on T lymphocytes in patients with acute graft-versus-host disease after allogeneic bone marrow transplantation.J Interferon Cytokine Res.2002;22(7):751-754.

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部